Works matching IS 10834389 AND DT 2024 AND VI 29 AND IP 2
Results: 21
Diagnosis by combination of endoscopic findings helps differentiate non‐Helicobacter pylori Helicobacter‐infected gastritis from Helicobacter pylori‐infected gastritis.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13070
- By:
- Publication type:
- Article
Helicobacter pylori enhances HLA‐C expression in the human gastric adenocarcinoma cells AGS and can protect them from the cytotoxicity of natural killer cells.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13069
- By:
- Publication type:
- Article
Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13067
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.12992
- Publication type:
- Article
Four cases of non‐Helicobacter pylori Helicobacter‐infected gastritis with duodenal spiral bacilli.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13083
- By:
- Publication type:
- Article
Prevalence of Helicobacter pylori infection among Slovenian children and adolescents: A prospective cohort study.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13082
- By:
- Publication type:
- Article
Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large‐scale, multicenter randomized controlled trial LCI‐FIND.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13080
- By:
- Publication type:
- Article
Dynamic changes in the gut microbiota after bismuth quadruple therapy and high‐dose dual therapy for Helicobacter pylori eradication.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13077
- By:
- Publication type:
- Article
14‐day tailored PCR‐guided triple therapy versus 14‐day non‐Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open‐label randomized noninferiority controlled trial.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13076
- By:
- Publication type:
- Article
Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13075
- By:
- Publication type:
- Article
A reconstructed genome‐scale metabolic model of Helicobacter pylori for predicting putative drug targets in clarithromycin and rifampicin resistance conditions.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13074
- By:
- Publication type:
- Article
Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13073
- By:
- Publication type:
- Article
Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF‐κB/IL8 pathway.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13072
- By:
- Publication type:
- Article
The role of microbiota in gastric cancer: A comprehensive review.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13071
- By:
- Publication type:
- Article
Research progress in photodynamic therapy for Helicobacter pylori infection.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13068
- By:
- Publication type:
- Article
Antagonizing roles of SHP1 in the pathogenesis of Helicobacter pylori infection.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13066
- By:
- Publication type:
- Article
Disruption of the gastric epithelial barrier in Correa's cascade: Clinical evidence via confocal endomicroscopy.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13065
- By:
- Publication type:
- Article
Volatilomic signatures of different strains of Helicobacter pylori.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13064
- By:
- Publication type:
- Article
Impact of mixed‐infection rate of clarithromycin‐susceptible and clarithromycin‐resistant Helicobacter pylori strains on the success rate of clarithromycin‐based eradication treatment.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13062
- By:
- Publication type:
- Article
Refractoriness to anti‐Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil‐Ecuador.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13060
- By:
- Publication type:
- Article
Meta‐analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
- Published in:
- Helicobacter, 2024, v. 29, n. 2, p. 1, doi. 10.1111/hel.13059
- By:
- Publication type:
- Article